Italia markets close in 49 minutes

FTSE MIB
33.589,32
-117,89(-0,35%)
Dow Jones
38.980,84
-131,32(-0,34%)
Nasdaq
17.747,25
+29,59(+0,17%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
80,73
-0,10(-0,12%)
Bitcoin EUR
57.598,19
-260,67(-0,45%)

NBIX Jul 2024 150.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,5500

-0,0500

(-8,33%)

In data: 02:45PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat